ZANAMIVIR: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036	NDA	GlaxoSmithKline LLC	0173-0681-01	5 PACKAGE in 1 CARTON (0173-0681-01) / 4 POWDER in 1 PACKAGE	1999-09-22
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036	NDA	GlaxoSmithKline LLC	0173-0681-22	5 PACKAGE in 1 CARTON (0173-0681-22) / 4 POWDER in 1 PACKAGE	1999-09-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for zanamivir, a neuraminidase inhibitor used to treat and prevent influenza A and B. It identifies key raw material suppliers, contract manufacturing organizations (CMOs), and examines the patent landscape impacting market access and competition.

Who Manufactures Zanamivir Active Pharmaceutical Ingredient (API)?

The production of zanamivir API is concentrated among a limited number of specialized manufacturers. These entities possess the requisite chemical synthesis capabilities and adhere to stringent regulatory standards.

Key API Manufacturers Identified:
- GlaxoSmithKline (GSK): As the originator company, GSK maintains significant in-house API manufacturing capacity for zanamivir, primarily for its branded product, Relenza.
- Generic API Producers: Several companies have entered the generic API market following patent expiries. These include:
  - Divi's Laboratories: A prominent Indian API manufacturer with a history of producing complex molecules, including neuraminidase inhibitors.
  - Aarti Industries: Another Indian pharmaceutical ingredient company that has been involved in the production of intermediates and APIs for antiviral drugs.
  - Neuland Laboratories: This Indian pharmaceutical company also has capabilities in complex chemical synthesis and API production.
  - Hetero Labs: A major Indian generic pharmaceutical company with API manufacturing facilities.
Geographic Concentration: The majority of generic zanamivir API production is located in India, driven by cost efficiencies and established expertise in pharmaceutical chemical manufacturing.
Regulatory Compliance: Manufacturers must comply with Good Manufacturing Practices (GMP) as stipulated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes rigorous quality control and documentation.

What Are the Key Raw Materials and Their Suppliers?

The synthesis of zanamivir involves a multi-step chemical process requiring specific starting materials and intermediates. Identifying these precursors and their suppliers is crucial for understanding supply chain vulnerabilities and cost drivers.

Primary Synthetic Route Intermediates:
- D-arabinose: A five-carbon sugar that forms a core part of the zanamivir molecule. This is often sourced from specialized carbohydrate manufacturers.
- Guanidine derivatives: Used to introduce the guanidino group.
- Pyrrole derivatives: Essential for forming the pyrrolidine ring structure.
- Carboxylic acid precursors: For building the carboxylate functionality.
Leading Suppliers of Key Intermediates: The supply of these intermediates is often fragmented and can involve fine chemical companies. Specific supplier names for proprietary intermediates are not publicly disclosed due to commercial confidentiality. However, general sourcing tends to originate from:
- Specialty Chemical Manufacturers: Companies focusing on chiral synthesis, carbohydrate chemistry, and nitrogen-containing heterocycles are key.
- Global Chemical Distributors: These entities often aggregate materials from various manufacturers.
Supply Chain Considerations:
- Quality and Purity: The purity of raw materials directly impacts the final API quality and yield. Suppliers must provide materials meeting stringent pharmacopeial standards.
- Reliability of Supply: Interruptions in the supply of critical intermediates can significantly impact API production timelines and costs.
- Geopolitical Risks: Concentration of certain intermediate suppliers in specific regions can introduce geopolitical risks.

Who are the Contract Manufacturing Organizations (CMOs) Involved in Zanamivir Production?

While GSK has in-house capabilities, the production of finished dosage forms (FDFs) and potentially some intermediates or API for generic markets often involves CMOs.

CMOs for Finished Dosage Forms (Relenza and Generics):
- CMOs play a critical role in formulating the API into the final inhaler product. This involves specialized equipment for dry powder inhaler (DPI) manufacturing.
- Companies like Catalent Pharma Solutions and Recipharm are known for their expertise in complex dosage forms, including DPIs, and may be involved in zanamivir production for various clients.
- Specific CMO partnerships are typically confidential, but companies with broad capabilities in sterile manufacturing, powder handling, and inhalation device filling are potential partners.
CMOs for API or Intermediates:
- Some generic companies may outsource specific synthesis steps or the entire API production to CMOs, particularly if they lack the specialized infrastructure or wish to optimize costs.
- These CMOs would be the same types of specialized chemical manufacturers identified in the API section, but operating under contract for a specific client.
Due Diligence Requirements: Pharmaceutical companies rigorously vet CMOs based on:
- Quality systems and regulatory compliance records.
- Technical capabilities and capacity.
- Financial stability and track record.
- Intellectual property protection protocols.

What is the Patent Landscape for Zanamivir?

The patent landscape for zanamivir has evolved significantly since its initial approval, influencing market exclusivity and the entry of generic competition.

Key Patents and Expiry Dates:
- Core Compound Patent: The primary patent covering the zanamivir compound itself has expired in major markets. For example, the foundational U.S. patent is long expired.
- Formulation Patents: Patents related to specific formulations, such as the dry powder inhaler delivery system, have also expired or are nearing expiry. This is a critical area for generic entry.
- Method of Use Patents: Patents covering specific therapeutic uses (e.g., prophylaxis in certain populations) may still be in force but are often challenging for generics to infringe upon directly.
- Manufacturing Process Patents: While less impactful for generic market entry if the core compound is off-patent, patents on novel or improved manufacturing processes can provide some level of protection.
Impact of Patent Expiry on Market Entry:
- The expiry of key composition of matter and formulation patents has paved the way for generic zanamivir products.
- First-to-File (FTF) Exclusivity: In some jurisdictions, the first generic company to successfully challenge patents and submit an Abbreviated New Drug Application (ANDA) or equivalent may be granted a period of market exclusivity.
- Patent Litigation: Generic manufacturers often initiate "Paragraph IV" certifications in the U.S., challenging existing patents. This frequently leads to patent litigation, with outcomes determining the timing of generic market entry.
Current Patent Status (General Overview):
- As of [Current Year - e.g., 2023], the primary patents protecting zanamivir as a chemical entity are expired globally.
- Patents specifically tied to the original Relenza inhaler device or specific manufacturing techniques may still be under consideration but are generally less of a barrier to generic API production.
- The focus for new patent filings would likely shift to novel delivery systems, combination therapies, or new therapeutic indications, which are less relevant to the current generic API supply chain.
Data Sources for Patent Analysis:
- USPTO Patent Database: United States Patent and Trademark Office.
- Espacenet: European Patent Office database.
- WIPO Patentscope: World Intellectual Property Organization database.
- National Patent Offices: Databases of individual countries.
- Commercial Patent Databases: Such as Derwent Innovation, Questel Orbit, or LexisNexis PatentSight for comprehensive analysis.

What Are the Regulatory Considerations for Zanamivir Supply?

The production and distribution of zanamivir, like all pharmaceuticals, are subject to extensive regulatory oversight to ensure safety, efficacy, and quality.

Good Manufacturing Practices (GMP):
- All manufacturing sites involved in API and FDF production must comply with current GMP standards. This includes detailed requirements for facilities, equipment, personnel, quality control, and documentation.
- FDA (U.S.), EMA (Europe), PMDA (Japan), CDSCO (India): These are key regulatory bodies whose GMP guidelines must be met.
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs):
- API manufacturers typically file DMFs or ASMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API.
- Pharmaceutical companies seeking to use an API must reference its DMF/ASMF in their drug product application.
ANDA / Marketing Authorization Applications:
- Generic drug applications (e.g., ANDAs in the U.S.) require demonstrating bioequivalence to the reference listed drug (RLD), typically Relenza.
- This involves submitting data on the API, formulation, manufacturing process, and stability.
Inspection and Audits:
- Regulatory agencies conduct routine inspections of manufacturing facilities.
- Pharmaceutical companies also conduct supplier audits to ensure compliance and quality assurance.
Supply Chain Security:
- Regulations increasingly focus on supply chain integrity, including measures against counterfeiting and ensuring traceability of materials.

What Are the Key Risks in the Zanamivir Supply Chain?

Several factors present risks to the reliable and cost-effective supply of zanamivir.

Raw Material Volatility:
- Price Fluctuations: The cost of specialized chemical intermediates can be subject to market demand, supply disruptions, and geopolitical factors affecting raw material extraction or processing.
- Supplier Dependency: Reliance on a limited number of suppliers for critical intermediates can create single-point-of-failure risks.
Manufacturing Capacity and Lead Times:
- Specialized Equipment: The production of inhalation products requires specialized and often expensive equipment, which may have long lead times for acquisition or expansion.
- Batch Sizes and Demand Spikes: Pharmaceutical demand can be unpredictable, particularly for antivirals influenced by seasonal influenza. Manufacturers must manage capacity to meet potential demand surges without significant overstocking.
Regulatory Compliance and Quality Issues:
- Inspection Failures: A manufacturing site failing regulatory inspection can halt production, leading to shortages.
- Recalls: Product recalls due to quality defects can damage reputation and incur significant financial losses.
- Changes in Regulations: Evolving regulatory requirements can necessitate costly upgrades to manufacturing processes or facilities.
Intellectual Property and Litigation:
- While core patents have expired, ongoing litigation related to secondary patents or manufacturing processes can create uncertainty.
- The threat of patent infringement lawsuits, even if ultimately unsuccessful, can deter investment or market entry.
Geopolitical and Environmental Factors:
- Trade Restrictions: Tariffs or trade disputes can impact the cost and availability of raw materials or finished goods.
- Environmental Regulations: Increasingly stringent environmental regulations can increase production costs or lead to the closure of non-compliant facilities.
- Natural Disasters: Events like earthquakes, floods, or pandemics can disrupt manufacturing operations.

Key Takeaways

The zanamivir supply chain is characterized by a concentration of API manufacturing in India, with GlaxoSmithKline retaining in-house production for its branded product. Generic API production relies on specialized chemical synthesis expertise. Key risks include raw material volatility, reliance on specific suppliers, manufacturing capacity constraints for dry powder inhalers, and ongoing regulatory compliance. The expiry of core patents has enabled generic competition, though the fragmented nature of intermediate supply and the specialized nature of DPI manufacturing present ongoing challenges.

Frequently Asked Questions

1. What is the primary driver for the cost of zanamivir API?

The cost of zanamivir API is primarily driven by the complexity of its multi-step chemical synthesis, the cost of specialized chiral intermediates, and the stringent quality control measures required for pharmaceutical production. The yield of each synthesis step also significantly impacts the overall cost.

2. How does the demand for zanamivir fluctuate?

Demand for zanamivir fluctuates significantly based on influenza season severity, public health recommendations, and the availability of alternative antiviral treatments such as oseltamivir (Tamiflu) and baloxavir marboxil (Xofluza). Pandemic influenza threats can also lead to stockpiling and surge demand.

3. What are the challenges in manufacturing the zanamivir dry powder inhaler (DPI)?

Manufacturing the zanamivir DPI presents challenges related to precise powder blending, particle size control, accurate dosing into the inhaler device, and ensuring the device's functionality and patient usability. This requires specialized expertise and equipment beyond standard solid dosage form manufacturing.

4. Are there significant barriers to entry for new generic zanamivir API manufacturers?

Yes, significant barriers exist. These include the substantial capital investment required for compliant manufacturing facilities, the need for highly skilled chemical synthesis teams, the cost and time involved in establishing reliable raw material supply chains, and the complex regulatory process for API approval (e.g., filing DMFs).

5. What impact has the rise of newer antiviral drugs had on the zanamivir supply chain?

The emergence of newer antiviral drugs with potentially different mechanisms of action, improved efficacy, or more convenient dosing regimens (e.g., oral tablets) can reduce the market share and overall demand for zanamivir. This can lead to reduced production volumes for both the API and finished product, potentially impacting the economics for manufacturers and suppliers in the zanamivir supply chain.

[1] U.S. Food and Drug Administration. (n.d.). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/ [2] European Medicines Agency. (n.d.). European Medicines Agency. Retrieved from https://www.ema.europa.eu/ [3] World Health Organization. (n.d.). World Health Organization. Retrieved from https://www.who.int/ [4] GlaxoSmithKline. (n.d.). Company Information. Retrieved from https://www.gsk.com/ [5] Divi's Laboratories. (n.d.). API Manufacturing Capabilities. Retrieved from https://www.divislabs.com/ [6] Aarti Industries. (n.d.). Pharmaceuticals Business. Retrieved from https://www.aarti-industries.com/ [7] Neuland Laboratories. (n.d.). API Manufacturing. Retrieved from https://www.neuland.com/ [8] Hetero Labs. (n.d.). API Manufacturing. Retrieved from https://www.hetero.com/ [9] United States Patent and Trademark Office. (n.d.). USPTO Patent Database. Retrieved from https://www.uspto.gov/patents/search [10] European Patent Office. (n.d.). Espacenet. Retrieved from https://worldwide.espacenet.com/ [11] World Intellectual Property Organization. (n.d.). WIPO Patentscope. Retrieved from https://patentscope.wipo.int/ [12] Catalent Pharma Solutions. (n.d.). Services. Retrieved from https://www.catalent.com/ [13] Recipharm. (n.d.). Services. Retrieved from https://www.recipharm.com/

Suppliers and packagers for generic pharmaceutical drug: ZANAMIVIR

ZANAMIVIR

Zanamivir Supply Chain: Key Manufacturers and Patent Landscape